Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Stimulus money to help sort out which medicines and treatments really work best

WASHINGTON — Think your doctor knows which drug — or surgery or even diagnostic test — works best? Think again.

Half the time, there's little if any good evidence comparing one with another. And one of medicine's little secrets is that new drugs don't have to work any better than cheap old ones to be approved for sale.

Now the government has a $1.1 billion down payment to start unraveling that problem, money provided in the economic stimulus package to better determine which test or treatment works best, when and for whom so patients don't waste time and money on poor choices.

But which ailments go to the top of a long wish list? And perhaps most important, how to make sure the results get into doctors' and patients' hands but not overly limit what therapies people can choose?

"There's a lot of clamor . . . that this is going to deprive people of the choice to basically have every treatment they want. That's based on a false premise," said Dr. Harold Sox, past president of the American College of Physicians. Last week, Sox was chosen to lead a panel of the prestigious Institute of Medicine to help guide what comparisons the government makes. "If people had a good explanation of why a test that they wanted was more likely to hurt them than to help them, they might of their free choice say, 'You know, I was clearly wrong. I shouldn't want that test and now I don't.' "

High-stakes comparisons

At issue is what's called "comparative effectiveness." Should you have bypass surgery or far less invasive stents to open severely clogged heart arteries? Which best prevents stroke from a clogged neck artery, surgically rooting out the clog or pushing it aside with a stent?

Does arthroscopic surgery work any better than painkillers for knee arthritis? Of all the competing pills, which is best to start with in treating Type 2 diabetes or high blood pressure? Is there really any difference between Prevacid and Prilosec for heartburn, or between Fosamax and hormone treatments for bone-weakening osteoporosis?

Those winners-and-losers questions drive fierce opposition to comparison-effectiveness research from drugmakers and others who have a financial stake in the outcome and fear that insurers will use the results to make coverage decisions. Back surgeons once lobbied to kill the federal Agency for Healthcare Research and Quality, or AHRQ, after it found "insufficient evidence" supporting certain spine operations — not that they didn't work, just that more evidence was needed.

The result: The nation has a scattershot method for determining best medicine. The little-known AHRQ spends about $30 million a year reviewing evidence of select tests and treatments. The National Institutes of Health occasionally compares contested therapies in expensive, years-long studies of thousands of patients, like the current stroke trial.

Helping the feds focus

So an extra $1.1 billion for the government to start spending on such comparisons this year marks a huge jump. By the end of June, the Institute of Medicine panel will provide a priority list of up to 50 vexing medical questions to help the feds determine where to start.

Don't expect easy answers. Federal scientists are acutely aware that many of today's studies don't account for wide variations in responses to treatments by minorities or other subgroups.

"Medical decisionmaking is rarely black-and-white," adds the NIH's heart chief Dr. Elizabeth Nabel. "We see certainly helping to provide additional evidence that really guides physicians and individuals in sorting through the shades of gray."

Stimulus money to help sort out which medicines and treatments really work best 03/11/09 [Last modified: Wednesday, March 11, 2009 5:53pm]
Photo reprints | Article reprints

Copyright: For copyright information, please check with the distributor of this item, Associated Press.
    

Join the discussion: Click to view comments, add yours

Loading...
  1. Search for missing Army helicopter crew suspended in Hawaii

    Military

    HONOLULU — Officials have suspended the search for five Army soldiers who were aboard a helicopter that crashed during offshore training in Hawaii last week.

    Water safety officials hand over possible debris from an Army UH-60 Black Hawk helicopter crash to military personnel stationed at a command center in a harbor, Wednesday in Haleiwa, Hawaii, a day after. an Army helicopter with five on board crashed several miles off Oahu's North Shore. Officials  suspended the search for five Army soldiers in a helicopter crash during offshore training in Hawaii on Monday. [Associated Press]
  2. Rubio praises Trump for 'excellent' speech on Afghanistan

    Blogs

    Sen. Marco Rubio praised President Donald Trump's "excellent" speech on Afghanistan. Sen. Bill Nelson was less effusive but agreed with the goal.

  3. Gov. Rick Scott blasts report of shifting words on Charlottesville

    Blogs

    Gov. Rick Scott, one of the most scripted politicians in modern Florida history, said Monday that ‘both sides” bore blame for Charlottesville.

  4. Record $417 million awarded in lawsuit linking baby powder to cancer

    Nation

    LOS ANGELES — A Los Angeles jury on Monday ordered Johnson & Johnson to pay a record $417 million to a hospitalized woman who claimed in a lawsuit that the talc in the company's iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene.

    A bottle of Johnson's baby powder is displayed. On Monday, Aug. 21, 2017, a Los Angeles County Superior Court spokeswoman confirmed that a jury has ordered Johnson & Johnson to pay $417 million in a case to a woman who claimed in a lawsuit that the talc in the company's iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene. [Associated Press]
  5. Search under way for missing sailors; Navy chief orders inquiry

    Military

    SINGAPORE — The U.S. Navy ordered a broad investigation Monday into the performance and readiness of the Pacific-based 7th Fleet after the USS John S. McCain collided with an oil tanker in Southeast Asian waters, leaving 10 U.S. sailors missing and others injured.

    Damage is visible as the USS John S. McCain steers toward Singapore’s naval base on Monday.